Skip to Content

LEVETIRACETAM ROSEMONT 100MG/ML ORAL SOLUTION

Active substance(s): LEVETIRACETAM

PDF options:  View Fullscreen   Download PDF

PDF Transcript

PACKAGE LEAFLET: INFORMATION FOR THE USER

LEVETIRACETAM ROSEMONT 100mg/ml ORAL SOLUTION
Levetiracetam

Read all of this leaflet carefully before you or your child start taking this medicine.
n Keep this leaflet. You may need to read it again.
n If you have any further questions, ask your doctor or pharmacist.
n This medicine has been prescribed for you. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours.
n If you get any side effects please tell your doctor or pharmacist. This includes possible side effects not listed in this leaflet. See section 4.
What is in this leaflet:
1. What Levetiracetam Rosemont is and what it is used for
2. What you need to know before you take Levetiracetam Rosemont
3. How to take Levetiracetam Rosemont
4. Possible side effects
5. How to store Levetiracetam Rosemont
6. Contents of the pack and other information

1. WHAT LEVETIRACETAM ROSEMONT IS AND WHAT IT IS USED FOR
Levetiracetam Rosemont 100mg/ml Oral Solution contains the active ingredient levetiracetam, which is an antiepileptic medicine (a medicine used
to treat seizures in epilepsy)
Levetiracetam is used:
n on its own in adults and adolescents from 16 years of age with newly diagnosed epilepsy, to treat a certain form of epilepsy. Epilepsy is a
condition where the patients have repeated fits (seizures). Levetiracetam is used for the epilepsy form in which the fits initially affect only one
side of the brain, but could thereafter extend to larger areas on both sides of the brain (partial onset seizure with or without secondary
generalisation). Levetiracetam has been given to you by your doctor to reduce the number of fits.
n as an add-on to other antiepileptic medicines to treat:
• partial onset seizures with or without generalisation in adults, adolescents, children and infants from one month of age
• myoclonic seizures (short, shock-like jerks of muscle or group of muscles) in adults and adolescents from 12 years of age with juvenile
myoclonic epilepsy
• primary generalised tonic-clonic seizures (major fits, including loss of consciousness) in adults and adolescents from 12 years of age with
idiopathic generalised epilepsy (the type of epilepsy that is thought to have a genetic cause).

2. WHAT YOU NEED TO KNOW BEFORE YOU TAKE LEVETIRACETAM ROSEMONT
Do not take levetiracetam
n If you are allergic to levetiracetam, pyrrolidone derivatives or any of the other ingredients of this medicine (listed in section 6).
Warnings and precautions:
Talk to your doctor before taking levetiracetam
n If you suffer from kidney problems, follow your doctor’s instructions. He/she may decide if your dose should be adjusted.
n If you notice any slow down in the growth or unexpected puberty development of your child, please contact your doctor.
n A small number of people being treated with anti-epileptics such as levetiracetam have had thoughts of harming or killing themselves. If you
have any symptoms of depression and/or suicidal ideation, please contact your doctor.
Children and adolescents
Levetiracetam Rosemont is not indicated in children and adolescents below 16 years on its own (monotherapy).
Other medicines and Levetiracetam Rosemont:
Tell your doctor or pharmacist if you are taking or have recently taken or might take any other medicines. Do not take macrogol (a drug used as
laxative) for one hour before and one hour after taking levetiracetam as this may results in a reduction of its effect.
Methotrexate
Concomitant administration of levetiracetam and methotrexate has been reported to decrease methotrexate clearance, resulting in increased/
prolonged blood methotrexate concentration to potentially toxic levels. Blood methotrexate and levetiracetam levels should be carefully monitored
in patients treated concomitantly with the two drugs.
Pregnancy and breast-feeding:
If you are pregnant or breastfeeding, think you may be pregnant or are planning to have a baby, ask your doctor for advice before taking this
medicine. Levetiracetam should not be used during pregnancy unless clearly necessary. A risk of birth defects to your unborn child cannot be
completely excluded. Levetiracetam has shown unwanted reproductive effects in animal studies at dose levels higher than you would need to
control your seizures. Breast-feeding is not recommended during treatment.
Driving and using machines:
Levetiracetam may impair your ability to drive or operate any tools or machinery, as it may make you feel sleepy. This is more likely at the
beginning of treatment or after an increase in the dose. You should not drive or use machines until it is established that your ability to perform
such activities is not affected.
Levetiracetam Rosemont contains methyl parahydroxybenzoate, propyl parahydroxybenzoate and maltitol:
Levetiracetam Rosemont includes methyl parahydroxybenzoate (E218) and propyl parahydroxybenzoate (E216) which may cause allergic reactions
(possibly delayed).
Levetiracetam Rosemont also contains maltitol. If you have been told by your doctor that you have an intolerance to some sugars, contact your
doctor before taking this medicinal product.

3. HOW TO TAKE LEVETIRACETAM ROSEMONT
Always take Levetiracetam Rosemont exactly as your doctor has told you. You should check with your doctor or pharmacist if you are not sure.
Levetiracetam must be taken twice a day, once in the morning and once in the evening, at about the same time each day. Take the oral solution
following your doctor’s instructions.
Monotherapy
Dose in adults and adolescents from 16 years of age:
Measure the appropriate dosage using the 10 ml syringe included in the package for patients 4 years and above.
General dose: Levetiracetam Oral Solution is taken twice daily, in two equally divided doses, each individual dose being measured between 5 ml
(500mg) and 15 ml (1500mg).
When you first start taking levetiracetam, your doctor will prescribe you a lower dose during 2 weeks before giving you the lowest general dose.
Add-on therapy
Dose in adults and adolescents (12 to 17 years) weighing 50 kg or more:
Measure the appropriate dosage using the 10 ml syringe included in the package for patients of 4 years and above.
General dose: Levetiracetam Oral Solution is taken twice daily, in two equally divided doses, each individual dose being measured between 5 ml
(500mg) and 15 ml (1500mg).
Dose in children 6 months and older:
Your doctor will prescribe the most appropriate pharmaceutical form of levetiracetam according to the age, weight and dose.
For children 6 months to 4 years, measure the appropriate dosage using the 3 ml syringe included in the package.
For children above 4 years, measure the appropriate dosage using the 10 ml syringe included in the package.
General dose: Levetiracetam Oral Solution is taken twice daily, in two equally divided doses, each individual dose being measured between 0.1 ml
(10mg) and 0.3 ml (30mg), per kg bodyweight of the child. (see table below for dose examples).
Dose in children 6 months and older:
Weight
Starting dose: 0.1 ml/kg twice daily
6 kg
0.6 ml twice daily
8 kg
0.8 ml twice daily
10 kg
1 ml twice daily
15 kg
1.5 ml twice daily
20 kg
2 ml twice daily
25 kg
2.5 ml twice daily
From 50 kg
5 ml twice daily

Maximum dose: 0.3 ml/kg twice daily
1.8 ml twice daily
2.4 ml twice daily
3 ml twice daily
4.5 ml twice daily
6 ml twice daily
7.5 ml twice daily
15 ml twice daily

Dose in infants (1 month to less than 6 months):
For infants 1 month to less than 6 months, measure the appropriate dosage using the 1 ml syringe included in the package.
General dose: Levetiracetam Oral Solution is taken twice daily, in two equally divided doses, each individual dose being measured between 0.07 ml
(7mg) and 0.21 ml (21mg), per kg bodyweight of the infant. (see table below for dose examples).
Dose in infants (1 month to less than 6 months):
Weight
4 kg
5 kg
6 kg
7 kg

Starting dose: 0.07 ml/kg twice daily
0.3 ml twice daily
0.35 ml twice daily
0.45 ml twice daily
0.5 ml twice daily

Maximum dose: 0.21 ml/kg twice daily
0.85 ml twice daily
1.05 ml twice daily
1.25 ml twice daily
1.5 ml twice daily
Continued overleaf

C9X4SRBJ4 (23LF01524PW)

YES

N/A

Method of administration:
After measuring the correct dose with an appropriate syringe, Levetiracetam Oral Solution may be diluted in a glass of water or baby’s bottle. You
may take it with or without food.
Instructions for use:
n Open the bottle: press the cap and turn it anticlockwise.
n Separate the adaptor from the syringe. Insert the adaptor into the bottle neck. Ensure it is well fixed.
n Take the syringe and put it in the adaptor opening. Turn the bottle upside down.
n Fill the syringe with a small amount of solution by pulling the piston down, then push the piston upward in order to remove any possible
bubble. Pull the piston down to the graduation mark corresponding to the quantity in millilitres (ml) prescribed by your doctor.
n Turn the bottle the right way up. Remove the syringe from the adaptor.
n Empty the contents of the syringe in a glass of water or baby’s bottle by pushing the piston to the bottom of the syringe.
n Drink the whole contents of the glass/baby’s bottle.
n Close the bottle with the plastic screw cap.
n Wash the syringe with water only.
Duration of treatment:
n Levetiracetam is used as a chronic treatment. You should continue levetiracetam treatment for as long as your doctor has told you.
n Do not stop your treatment without your doctor’s advice as this could increase your seizures.
If you take more Levetiracetam Oral Solution than you should:
The possible side effects of an overdose of levetiracetam are sleepiness, agitation, aggression, decrease of alertness, inhibition of breathing and coma.
Contact your doctor if you took more levetiracetam than you should. Your doctor will establish the best possible treatment of overdose.
If you forget to take Levetiracetam Oral Solution:
Contact your doctor if you have missed one or more doses. Do not take a double dose to make up for a forgotten dose.
If you stop taking Levetiracetam Oral Solution:
If stopping treatment, levetiracetam should be discontinued gradually to avoid an increase of seizures. Should your doctor decide to stop your
Levetiracetam treatment, he/she will instruct you about the gradual withdrawal of Levetiracetam.
If you have any further questions on the use of this product, ask your doctor or pharmacist.

4. POSSIBLE SIDE EFFECTS
Like all medicines, this medicine can cause side effects, although not everybody gets them.
Tell your doctor immediately, or go to your nearest emergency department, if you experience:
n weakness, feel light-headed or dizzy or have difficulty breathing, as these may be signs of a serious allergic (anaphylactic) reaction
n swelling of the face, lips, tongue and throat (Quincke’s oedema)
n flu-like symptoms and a rash on the face followed by an extended rash with a high temperature, increased levels of liver enzymes seen in blood
tests and an increase in a type of white blood cell (eosinophilia) and enlarged lymph nodes (Drug Reaction with Eosinophilia and Systemic
Symptoms [DRESS])
n symptoms such as low urine volume, tiredness, nausea, vomiting, confusion and swelling in the legs, ankles or feet, as this may be a sign of
sudden decrease of kidney function
n a skin rash which may form blisters and look like small targets (central dark spots surrounded by a paler area, with a dark ring around the edge)
(erythema multiforme)
n a widespread rash with blisters and peeling skin, particularly around the mouth, nose, eyes and genitals (Stevens-Johnson syndrome)
n a more severe form of rash causing skin peeling in more than 30% of the body surface (toxic epidermal necrolysis)
n signs of serious mental changes or if someone around you notices signs of confusion, somnolence (sleepiness), amnesia (loss of memory),
memory impairment (forgetfulness), abnormal behaviour or other neurological signs including involuntary or uncontrolled movements. These
could be symptoms of an encephalopathy.
The most frequently reported adverse reactions were nasopharyngitis, somnolence (sleepiness), headache, fatigue and dizziness. At the beginning
of the treatment or at dose increase side effects like sleepiness, tiredness and dizziness may be more common. These effects should however
decrease over time.
Very common: (may affect more than 1 user in 10 people)
n nasopharyngitis;
n somnolence (sleepiness), headache.
Common: (may affect 1 to 10 users in 100 people)
n anorexia (loss of appetite);
n depression, hostility or aggression, anxiety, insomnia, nervousness or irritability;
n convulsion, balance disorder (equilibrium disorder), dizziness (sensation of unsteadiness), lethargy (lack of energy and enthusiasm), tremor
(involuntary trembling);
n vertigo (sensation of rotation);
n cough;
n abdominal pain, diarrhoea, dyspepsia (indigestion), vomiting, nausea;
n rash;
n asthenia/fatigue (tiredness).
Uncommon: (may affect 1 to 10 users in 1,000 people)
n decreased number of blood platelets, decreased number of white blood cells;
n weight decrease, weight increase;
n suicide attempt and suicidal ideation, mental disorder, abnormal behaviour, hallucination, anger, confusion, panic attack, emotional instability/
mood swings, agitation;
n amnesia (loss of memory), memory impairment (forgetfulness), abnormal coordination/ataxia (impaired coordinated movements), paraesthesia
(tingling), disturbance in attention (loss of concentration);
n diplopia (double vision), vision blurred;
n elevated/abnormal values in a liver function test;
n hair loss, eczema, pruritus;
n muscle weakness, myalgia (muscle pain);
n injury.
Rare: (may affect 1 to 10 users in 10,000 people)
n infection;
n decreased number of all blood cell types;
n decreased blood sodium concentration;
n suicide, personality disorders (behavioural problems), thinking abnormal (slow thinking, unable to concentrate);
n uncontrollable muscle spasms affecting the head, torso and limbs, difficulty in controlling movements, hyperkinesia (hyperactivity);
n pancreatitis;
n liver failure, hepatitis;
n rhabdomyolysis (breakdown of muscle tissue) and associated blood creatine phosphokinase increase. Prevalence is significantly higher in
Japanese patients when compared to non-Japanese patients.
Reporting of side effects
If you get any side effects talk to your doctor or pharmacist. This includes any possible side effects not listed in the leaflet. You can also report side
effects directly via the Yellow Card Scheme at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App
Store. By reporting side effects you can help provide more information on the safety of this medicine.

5. HOW TO STORE LEVETIRACETAM ROSEMONT
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiry date stated on the carton and bottle after EXP:.
The expiry date refers to the last day of the month. Do not use after 1 month of first opening the bottle. Store below 25°C. Store in the original
bottle, in order to protect from light.
Do not throw away medicines via wastewater or household waste. Ask your pharmacist how to throw away any medicines you no longer use.
These measures will help to protect the environment.

6. CONTENTS OF THE PACK AND OTHER INFORMATION
What Levetiracetam Rosemont contains
The active substance is called levetiracetam. Each 1 ml contains 100 mg of levetiracetam.
The other ingredients are: Sodium citrate, Citric acid, Methyl parahydroxybenzoate (E218), Propyl parahydroxybenzoate (E216), Ammonium
glycyrrhizate, Glycerol (E422), Maltitol (E965), Acesulfame potassium (E950), Grape flavour, Purified water.
What Levetiracetam Rosemont looks like and contents of the pack
Levetiracetam Rosemont 100 mg/ml Oral Solution is a clear liquid. The 300 ml glass bottle of Levetiracetam Rosemont (for children aged 4 years and
above, adolescents and adults) is packed in a cardboard box containing a 10 ml oral syringe (graduated every 0.25 ml) and an adaptor for the syringe.
The 150 ml glass bottle of Levetiracetam Rosemont (for infants and young children aged from 6 months to less than 4 years) is packed in a
cardboard box containing a 3 ml syringe (graduated every 0.1 ml) and an adaptor for the syringe.
The 150 ml glass bottle of Levetiracetam Rosemont (for infants aged 1 month to less than 6 months) is packed in a cardboard box containing a 1 ml
syringe (graduated every 0.05 ml) and an adaptor for the syringe.
Marketing Authorisation Holder and Manufacturer: Rosemont Pharmaceuticals Ltd., Leeds, LS11 9XE, UK.
PL Number: 00427/0244
This leaflet was last updated on 01/2018
C9X4SRBJ4 (23LF01524PW)

ARTWORK
VERSION:

+ Expand Transcript

Source: Medicines and Healthcare Products Regulatory Agency

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.

Hide